Anxiety + Mood Support

This protocol is for SUB-CLINICAL anxiety and low mood — the everyday load that doesn't meet diagnostic criteria for a mental-health condition but still degrades quality of life: persistent work-related anxiety, situational stress around life transitions, low-grade mood flatness without anhedonia or suicidal ideation. It assumes lifestyle anchors are in place (sleep, movement, daylight exposure, real-life social contact) or are being worked on alongside.

It is NOT a substitute for standard care. If you meet diagnostic criteria for major depressive disorder, generalized anxiety disorder severe enough to need treatment, PTSD, panic disorder, bipolar disorder, OCD, or any other psychiatric diagnosis, the answer is a clinician (therapist + prescriber as appropriate) — not this protocol. Peptides are not a replacement for SSRI, SNRI, lamotrigine, lithium, or any other evidence-based psychiatric medication.

If you have any current suicidal ideation, self-harm thoughts, or active substance-use crisis, the answer is crisis care — call or text 988 (US Suicide & Crisis Lifeline) or your local equivalent. Stop reading this and get that help first.

Phases

1. Phase 1 — Anxiolytic foundation (Selank)

   weeks 1-4

   Selank 250mcg intranasal three times daily (750mcg/day total) — the dose pattern from the Russian clinical literature (Zozulya 2008 reported anxiolytic effects comparable to medazepam at this range). Effects emerge gradually over 2-3 weeks; this is NOT a fast-acting benzodiazepine substitute. The right read is at 4 weeks, not at 4 days. Continue lifestyle anchors (sleep, movement, daylight, social contact) throughout — peptides are an adjunct, not a replacement.

   • Selank250 mcg · three times daily · morning + midday + evening (intranasal)

     250mcg per intranasal dose, three times daily — 750mcg total daily. Middle of the Russian clinical range (250-900mcg/day). Split-dose pattern keeps peptide presence relatively steady through the day; some users do well at 2x/day if 3x feels burdensome. See Juno's nasal-spray prep guide for handling specifics — Selank handling matters because the intact peptide is short-lived in solution.

   What “working” looks like

   Reduced background anxiety load over 2-4 weeks. Less reactive to small stressors that previously felt larger than they were. Sleep onset modestly easier (anxiety quieting before bed). Subjectively: 'I'm noticing I'm not running the same loops as much.' Important: Selank is non-sedating and non-addictive — it doesn't deliver the immediate quiet a benzodiazepine does, which is a feature, not a bug. If you're expecting benzo-like acute relief, you'll be disappointed; this is slower and steadier.

   Decision criteria

   After 4 weeks of Phase 1: if you have meaningful background-anxiety reduction, this is your working dose — continue. Most users see the value in cycling (e.g., 4-8 weeks on, 4-8 weeks off) rather than continuous use, because the chronic-use safety data is essentially absent outside Russian clinical contexts. If only partial improvement and the bottleneck is mood-baseline + cognitive load (rumination, motivational flatness), consider Phase 2. If no improvement after 4 weeks: discontinue and revisit — Selank's clinical signal in published trials is modest; if it's not working in your physiology, escalating won't change that.

2. Phase 2 — Cognitive-anxiety + mood-baseline layer (+Semax, optional)

   weeks 4-12

   OPTIONAL. Add Semax 600mcg intranasal once daily (morning) layered on continued Selank. The pairing is Russian-clinical tradition — Selank for anxiolytic effect + Semax for cognitive-attention + mood-baseline support. Mechanistically: BDNF/NGF modulation + enkephalinase inhibition + serotonergic + dopaminergic tone. Use only when Phase 1 has plateaued and the residual presentation is more cognitive-rumination + flat-mood than acute-anxiety. Continue Selank Phase 1 dose throughout.

   • Selank250 mcg · three times daily · morning + midday + evening (intranasal)

     Continue Phase 1 dose throughout Phase 2 — the anxiolytic foundation stays in place.

   • Semax600 mcg · once daily · morning (intranasal)

     600mcg intranasal once daily, morning — the low end of the Russian clinical range for nootropic use (600mcg/day for 'general' nootropic; up to 12mg/day in acute stroke protocols, which is NOT this indication). Morning dosing avoids any evening activation that could interfere with sleep onset (Selank's anxiolytic effect handles the evening side).

   What “working” looks like

   Mood baseline lifts modestly over 2-4 weeks of Phase 2 — less flat, more responsive to positive stimuli. Cognitive load eases (fewer rumination loops; easier to disengage from anxiety thoughts when they arise). Attention quality during the workday improves. The combined effect is not dramatic — Semax is a subtle nootropic in most users, not an obvious stimulant — but the editorial pattern is 'I'm doing better, hard to point at exactly when it shifted.'

   Decision criteria

   After 8-12 weeks of Phase 1+2 combined: if you have meaningful improvement on both axes (anxiety + mood baseline), this is your working stack — taper to cycling rhythm. If anxiety improved but mood didn't shift, Semax isn't doing the lifting in your physiology — drop Phase 2 and continue Phase 1 alone. If neither anxiety nor mood improved after the full cycle: this protocol isn't working for you — discontinue and revisit standard care (therapy + clinician consultation about whether you've been managing a sub-clinical presentation that actually warrants formal treatment).

Often combined with

• Cognitive Sharpness

  Semax is in both protocols (Cognitive Sharpness Phase 2 + Anxiety + Mood Phase 2). If running both, do NOT double-dose — single 600mcg/day morning dose covers both surfaces. Users running both typically have cognitive load with strong anxiety undercurrent (e.g., high-pressure work with rumination); the Cognitive protocol's broader nootropic stack (cerebrolysin, etc.) may add value the anxiety surface alone doesn't.

• Sleep Optimization

  Anxiety and sleep disruption are tightly coupled — anxiety drives insomnia drives more anxiety. If sleep onset is the dominant symptom and daytime anxiety is secondary, consider whether the Sleep protocol (epithalon + DSIP) addresses the upstream cause more directly. Run both together if both axes are present; the peptide sets don't overlap.